| 101 |
NCT02870738 |
Recruiting |
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS |
- Cystitis, Interstitial
- Painful Bladder Syndrome
|
- Procedure: Pelvic Floor Physical Therapy
- Drug: Bladder Instillations
|
Interventional |
Phase 2 |
- William Beaumont Hospitals
- Baylor College of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Markedly/Moderately Improved on Global Response Assessments
- Change in symptoms
|
128 |
Female |
18 Years to 85 Years (Adult, Senior) |
NCT02870738 |
2016-253 |
|
April 21, 2017 |
August 2019 |
August 2020 |
August 17, 2016 |
March 6, 2018 |
|
- William Beaumont Hospital
Royal Oak, Michigan, United States
|
| 102 |
NCT02379806 |
Recruiting |
The SYMPTOMS - SYstematic Elderly Medical Patients Thromboprophylaxis: Efficacy on Symptomatic OutcoMeS - Study |
|
- Drug: Enoxaparin
- Drug: Placebo
|
Interventional |
Phase 3 |
- University Hospital, Brest
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Composite of the following events: symptomatic confirmed deep venous thrombosis (DVT), symptomatic confirmed pulmonary embolism (PE), or fatal PE
- Composite of the following events: Major bleeding, clinically relevant non major bleeding, symptomatic confirmed VTE (DVT or PE) or fatal PE, atherothrombotic cardiovascular events, cardiovascular death, Death from any cause.
|
5030 |
All |
70 Years and older (Senior) |
NCT02379806 |
RB14.012 SYMPTOMS
2014-000311-13 |
SYMPTOMS |
September 2015 |
September 2018 |
December 2018 |
March 5, 2015 |
April 20, 2018 |
|
- Centre Hospitalier d'Agen
Agen, France - CHU Angers
Angers, France - CH Angoulême
Angouleme, France - (and 51 more...)
|
| 103 |
NCT03191305 |
Not yet recruiting |
Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis |
- Cerebral Venous Thrombosis
|
- Drug: Coumadin
- Drug: Rivoroxaban
|
Interventional |
Not Applicable |
- Foundation University Islamabad
- Shaheed Zulfiqar Ali Bhutto Medical University
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Hemorrhage or Recurrent CVT based on repeat MRI.
- Cost
|
50 |
All |
13 Years to 50 Years (Child, Adult) |
NCT03191305 |
FUI/CTR/2017/2 |
CVT |
August 2017 |
September 2018 |
September 2018 |
June 19, 2017 |
June 19, 2017 |
|
|
| 104 |
NCT03203421 |
Recruiting |
A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2 |
|
- Biological: ChAdOx1 LS2
- Biological: MVA LS2
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- The safety and tolerability of ChAdOx1 LS2 administered alone and with MVA LS2 in a prime-boost vaccination regimen in healthy malaria-naive volunteers assessed by the frequency and severity of adverse events.
- The efficacy of ChAdOx2 LS2 and MVA LS2 administered in a prime-boost vaccination regimen against malaria sporozoite challenge, in healthy malaria-naive volunteers.
|
31 |
All |
18 Years to 45 Years (Adult) |
NCT03203421 |
VAC067 |
|
July 3, 2017 |
September 2018 |
September 2018 |
June 29, 2017 |
August 2, 2017 |
|
- CCVTM, University of Oxford, Churchill Hospital
Oxford, United Kingdom
|
| 105 |
NCT01605409 |
Recruiting |
Emergency Cardiopulmonary Bypass for Cardiac Arrest |
|
- Procedure: Emergency cardiopulmonary bypass under ongoing CPR
- Procedure: Standard ACLS
|
Interventional |
Not Applicable |
- Medical University of Vienna
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of return of spontaneous circulation (ROSC)
|
40 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01605409 |
KLI196 |
ECPB4OHCA |
November 2014 |
December 2020 |
May 2021 |
May 24, 2012 |
March 26, 2018 |
|
- Medical University Vienna, Dept. of Emergency Medicine
Vienna, Austria
|
| 106 |
NCT02744092 |
Recruiting |
Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer |
- Cancer
- Venous Thromboembolism
- Deep Vein Thrombosis (DVT)
- (and 2 more...)
|
- Drug: Rivaroxaban
- Drug: Apixaban
- Drug: Edoxaban
- (and 5 more...)
|
Interventional |
Not Applicable |
- Alliance Foundation Trials, LLC.
- Patient-Centered Outcomes Research Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cumulative VTE recurrence reported by participants (via study-specific questionnaire) or clinicians (via study-specific case report form)
- Cumulative rates of major bleeding reported by participants (via study-specific questionnaire) or clinicians (via study-specific case report form)
- Health related quality of life reported by participants via the Optum SF-12v2 Health Survey questionnaire
- (and 2 more...)
|
940 |
All |
21 Years and older (Adult, Senior) |
NCT02744092 |
AFT-28
CER-1503-29805 |
CANVAS |
December 2016 |
September 2019 |
September 2019 |
April 20, 2016 |
April 13, 2018 |
|
- VA Central California Fresno Medical Center
Fresno, California, United States - UCSF Medical Center - Mission Bay
San Francisco, California, United States - Saint Joseph's Medical Center
Stockton, California, United States - (and 117 more...)
|
| 107 |
NCT02338947 |
Not yet recruiting |
Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients |
- Coronary Artery Disease
- Complications Due to Coronary Artery Bypass Graft
- Fragility
|
- Procedure: Off-Pump Coronary-Artery Bypass Grafting
- Procedure: On-Pump Coronary-Artery Bypass Grafting
|
Interventional |
Not Applicable |
- University of Sao Paulo General Hospital
- Instituto de Cardiologia do Distrito Federal
- Instituto do Coração da Faculdade de Medicina da Universidade de São Paulo
- (and 8 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The primary purpose of this study is to compare adverse cardiac and cerebrovascular events after OPCAB and CABG in pre-frail and frail patients
- Major Adverse Cardiac and Cerebrovascular events after OPCAB and CABG in pre-frail and frail patients
- Operative Time
- (and 14 more...)
|
630 |
All |
65 Years and older (Adult, Senior) |
NCT02338947 |
USaoPauloGH1000
Sao Paulo Research Foundation |
FRAGILE |
January 1, 2018 |
December 31, 2020 |
March 31, 2021 |
January 15, 2015 |
October 26, 2017 |
|
- USP Heart Institute
São Paulo, Brazil
|
| 108 |
NCT03114722 |
Not yet recruiting |
Citrate 4% Versus Heparinised Saline in Preventing Peripherally Inserted Central Catheter (PICC) Occlusions |
|
- Drug: Citrate 4%
- Drug: Heparinised saline (10U/ml)
|
Interventional |
Phase 2 |
- National University Hospital, Singapore
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Rate of catheter occlusion
- Line troubleshooting
- Catheter associated bacteraemia
- Bleeding complications
|
130 |
All |
21 Years to 99 Years (Adult, Senior) |
NCT03114722 |
2016/01420 |
|
July 31, 2017 |
July 31, 2018 |
December 30, 2018 |
April 14, 2017 |
June 15, 2017 |
|
- Nationa University Hospital
Singapore, Singapore
|
| 109 |
NCT01573169 |
Recruiting |
PREvention of VENous Thromboembolism In Hemorrhagic Stroke Patients |
- Hemorrhagic Stroke
- Venous Thromboembolism
- Deep Venous Thrombosis
|
- Drug: Enoxaparin
- Other: Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Symptomatic and asymptomatic venous thromboembolism
- Bleedings
- mortality
- disability
|
406 |
All |
18 Years and older (Adult, Senior) |
NCT01573169 |
PREVENTIHS |
PREVENTIHS |
May 2012 |
December 2020 |
December 2020 |
April 6, 2012 |
October 11, 2017 |
|
- Stroke Unit
Perugia, Italy
|
| 110 |
NCT02653092 |
Recruiting |
Reprometabolic Syndrome Mediates Subfertility in Obesity |
- Obesity
- Infertility
- Hypogonadotropic Hypogonadotropism
- Hyperinsulinemia
|
- Drug: Insulin
- Drug: Intralipid
- Drug: Dextrose
- (and 3 more...)
|
Interventional |
Not Applicable |
- University of Colorado, Denver
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change in LH pulse amplitude
|
30 |
Female |
18 Years to 38 Years (Adult) |
NCT02653092 |
15-1052
UL1TR001082 |
|
June 2016 |
March 2018 |
March 2019 |
January 12, 2016 |
August 31, 2017 |
|
- University of Colorado Denver
Aurora, Colorado, United States
|
| 111 |
NCT03187743 |
Not yet recruiting |
Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone |
- Lupus Erythematosus, Systemic
|
|
Interventional |
Not Applicable |
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- SELENA-SLEDAI score
- Primary parameters : volume of distribution
- Primary parameters : elimination clearance
- (and 6 more...)
|
120 |
All |
6 Years and older (Child, Adult, Senior) |
NCT03187743 |
P160935J
2017-002050-36 |
DECOR |
May 2018 |
February 2021 |
November 2021 |
June 15, 2017 |
April 17, 2018 |
|
- Hospital Necker Enfants Malades
Paris, France
|
| 112 |
NCT03143647 |
Not yet recruiting |
Magnesium and Platelet Function Testing |
|
- Other: Collect a study-specific blood sample of healthy subjects
|
Observational |
|
- Ziekenhuis Oost-Limburg
- Maastricht University
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
20 |
Female |
18 Years to 50 Years (Adult) |
NCT03143647 |
CTU2017140 |
MgCedVD |
May 24, 2017 |
April 2018 |
April 2018 |
May 8, 2017 |
May 30, 2017 |
|
|
| 113 |
NCT03251963 |
Recruiting |
Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients |
- Venous Thromboembolism
- Deep Venous Thrombosis
- Surgery
|
- Drug: Fixed Dose Enoxaparin
- Drug: Variable Dose Enoxaparin
|
Interventional |
Phase 2 |
- University of Utah
- University of Michigan
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of Participants With Venous Thromboembolism Events
- Number of Participants With Bleeding Events
- Time to Venous Thromboembolism Event or Major Bleeding Event
|
116 |
All |
18 Years and older (Adult, Senior) |
NCT03251963 |
100484 |
|
September 15, 2017 |
August 2019 |
August 2019 |
August 16, 2017 |
October 27, 2017 |
|
- University of Utah
Salt Lake City, Utah, United States
|
| 114 |
NCT02412982 |
Recruiting |
Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients |
- Traumatic Injury
- Venous Thromboembolism
|
- Drug: Enoxaparin 40 mg q12h
- Drug: Enoxaparin 30 mg q8h
|
Interventional |
Phase 4 |
- University of Cincinnati
- United States Air Force
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Initial AT-III activity -- control group vs. other two groups combined
- Goal anti-Xa attainment / first repeat assessment
|
200 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02412982 |
Droege2015 |
|
March 2016 |
May 2018 |
July 2018 |
April 9, 2015 |
October 25, 2017 |
|
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
|
| 115 |
NCT03497338 |
Recruiting
New |
New Anticoagulation Strategies of VV-ECMO |
|
- Diagnostic Test: thrombelastogram，D-Dimer，APTT
|
Interventional |
Not Applicable |
- Xiao Tang
- Beijing Chao Yang Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Percentage of Participants with hemorrhage events
|
110 |
All |
18 Years and older (Adult, Senior) |
NCT03497338 |
new anticoagulation of ECMO |
|
April 1, 2018 |
December 30, 2020 |
December 30, 2020 |
April 13, 2018 |
April 13, 2018 |
|
- Department of respiratory and critical care medicine,Beijing Chao-yang Hospital
Beijing, Beijing, China
|
| 116 |
NCT02895373 |
Recruiting |
PGE1 as Additive Anticoagulant in ECMO-Therapy |
- Respiratory Distress Syndrome, Adult
- Extracorporeal Membrane Oxygenation
|
- Drug: Alprostadil
- Drug: 0.9% sodium chloride solution
|
Interventional |
Phase 2 |
- Thomas Staudinger
- Medical University of Vienna
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Bleeding rate (quantified by the number of packed red blood cells transfused in relation to the duration of ECMO therapy)
- number of bleeding incidences and severity of bleeding (bleeding grades)
- Number of Clotting Events
- (and 16 more...)
|
114 |
All |
18 Years and older (Adult, Senior) |
NCT02895373 |
ECMO_PGE1_2.1 |
ECMO_PGE1 |
July 2016 |
July 2019 |
October 2019 |
September 9, 2016 |
September 13, 2016 |
|
- Medical University of Vienna, Department of Medicine I, Intensive Care Unit
Vienna, Austria
|
| 117 |
NCT02873338 |
Recruiting |
Randomized Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia |
|
- Drug: CX-01
- Drug: Idarubicin
- Drug: Cytarabine
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Morphologic complete remission evaluated by IWG criteria (ANC >1000/microliter; platelet count >100,000, <5% blasts in bone marrow aspirate, no blasts with Auer rods, no evidence of extramedullary disease
- Event-free survival (length of time from randomization through treatment failure)
- Leukemia-free survival (length of time from the date of randomization until disease relapse or patient death from any cause, whichever comes first, in patients who achieve complete remission only)
- (and 8 more...)
|
75 |
All |
60 Years and older (Adult, Senior) |
NCT02873338 |
CNTX-CX-01-2015-AML-1 |
|
August 2016 |
May 2018 |
July 2018 |
August 19, 2016 |
December 28, 2017 |
|
- University of California, San Diego, Moores Cancer Center
La Jolla, California, United States - Colorado Blood Cancer Institute
Denver, Colorado, United States - George Washington University
Washington, District of Columbia, United States - (and 21 more...)
|
| 118 |
NCT02607111 |
Recruiting |
A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients |
|
|
Interventional |
Phase 4 |
- Lawson Health Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- The mean dalteparin dose for the daily home hemodialysis patients
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT02607111 |
107283 |
|
August 2016 |
January 2018 |
July 2018 |
November 17, 2015 |
September 12, 2016 |
|
- London Health Sciences Centre
London, Ontario, Canada
|
| 119 |
NCT03040063 |
Recruiting |
Complex Endovascular Approach to Treatment of Patients With Aneurysm of Popliteal Artery |
- Aneurysm; Popliteal Artery
- Limb Ischemia
|
- Procedure: Combined endovascular approach (EVAR)
- Procedure: Standard optimal therapy (OPT)
|
Interventional |
Not Applicable |
- Charles University, Czech Republic
- Petr Varejka
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Limb salvage in 12 months
- Patency of the popliteal artery in 12 months
|
30 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03040063 |
EVAR-P |
EVAR-P |
August 1, 2016 |
August 1, 2018 |
August 1, 2020 |
February 2, 2017 |
February 2, 2017 |
|
- Charles University in Prague
Prague, Czech Republic
|
| 120 |
NCT02979561 |
Recruiting |
Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy |
- Angiographically Confirmed Acute Massive Pulmonary Embolism Treated With Endovascular Mechanical Fragmentation and Thrombolytic Therapy
|
- Drug: Dabigatran Etexilate
- Drug: Warfarin
|
Interventional |
Phase 4 |
- Meshalkin Research Institute of Pathology of Circulation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- recurrent PE
- death
- hemorrhagic complications
- (and 2 more...)
|
200 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02979561 |
RE-SPIRE study |
Re-Spire |
October 2016 |
June 2018 |
June 2018 |
December 1, 2016 |
December 20, 2016 |
|
- Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology
Novosibirsk, Russian Federation
|
| 121 |
NCT02743052 |
Recruiting |
Anticoagulation in Cancer Related Stroke |
|
- Drug: Anticoagulation treatment.
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Recurrent stroke or systemic embolism
- 90-days modified Rankin Scale score
- Effect of anticoagulation treatment
- Symptomatic hemorrhagic transformation
|
400 |
All |
20 Years and older (Adult, Senior) |
NCT02743052 |
SMC 2016-02-104 |
OASIS-CANCER |
October 2009 |
December 2018 |
December 2018 |
April 19, 2016 |
April 19, 2016 |
|
- Samsung Medical Center, Sungkyunkwan University School of Medicine
Seoul, Korea, Republic of
|
| 122 |
NCT02731794 |
Recruiting |
On-pump Beating Coronary Artery Bypass Grafting by Ventricular Assist |
|
- Device: left ventricular assist
- Procedure: Biventricular assist
|
Interventional |
Phase 4 |
- Henan Institute of Cardiovascular Epidemiology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Changes of C-reactive protein (CRP)
- Incidence of atrial fibrillation
- Durations of mechanical ventilation
- (and 4 more...)
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT02731794 |
HenanICE201602 |
|
May 2016 |
June 2018 |
August 2018 |
April 8, 2016 |
March 2, 2018 |
|
- Henan Provincial People' Hospital
Zhengzhou, Henan, China
|
| 123 |
NCT03309137 |
Not yet recruiting |
Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients |
- Infection
- Heart; Surgery, Heart, Functional Disturbance as Result
- Bacteremia
|
- Device: Chlorhexidine flush
|
Interventional |
Not Applicable |
- Alison Fox-Robichaud
- Dr. Richard Whitlock
- Dr. Julian Owen
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Compliance with the protocol
- Bacteremia
- Bacteria colonization of central line
|
100 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03309137 |
3654 |
CHG-Lock™ |
October 2017 |
October 2018 |
January 2019 |
October 13, 2017 |
October 13, 2017 |
|
- Hamilton Health Sciences
Hamilton, Ontario, Canada
|
| 124 |
NCT02069275 |
Recruiting |
Immediate Mobilization After Cardiac Catheterisation |
- Vascular Access Complication
- Comfort
|
- Other: Immediate mobilization
- Other: Two hours bedrest
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Hematoma> 5 cm
- The presence of hematoma> 10 cm in diameter
- The presence of hematoma 2-5 cm in diameter
- (and 2 more...)
|
2000 |
All |
18 Years and older (Adult, Senior) |
NCT02069275 |
SAMOVAR 01 |
SAMOVAR |
April 2013 |
November 2016 |
December 2016 |
February 24, 2014 |
July 1, 2016 |
|
- Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark
|
| 125 |
NCT03062241 |
Recruiting |
Ablation of Atrial Fibrillation in Heart Failure Patients |
- Atrial Fibrillation
- Severe Heart Failure
|
|
Interventional |
Not Applicable |
- Medical University of Silesia
- Military Institute of Medicine, Poland
- Clinical Hospital No. 2 Pomeranian Medical University, Szczecin, Poland
- Hospital name Pope John Paul, Zamosc, Poland
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Composite outcome of hospitalization due to heart failure worsening, mortality, use of mechanical left ventricle support and heart transplant.
- Percentage of patients who had ischaemic cerebral stroke during 12 months follow up
|
330 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT03062241 |
CONTRA-HF study |
CONTRA-HF |
January 23, 2017 |
July 31, 2018 |
July 31, 2019 |
February 23, 2017 |
November 7, 2017 |
|
- Department of Cardiology, Congenital Heart Diseases and Electrotherapy Medical University of Silesia, Silesian Center of Heart Diseases
Zabrze, Poland
|
| 126 |
NCT03182855 |
Not yet recruiting |
Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI |
- Acute Coronary Syndrome
- Myocardial Infarction
- STEMI - ST Elevation Myocardial Infarction
|
- Drug: Ticagrelor
- Drug: Cangrelor Tetrasodium
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Platelet reactivity 10 minutes PCI after is initiated
- Platelet reactivity before and after PCI
- Proportion of patients with inappropriate or harmful P2Y12 administration
|
80 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03182855 |
2016-003721-41 |
CanTi |
November 1, 2017 |
June 1, 2018 |
August 1, 2018 |
June 9, 2017 |
September 15, 2017 |
|
- Aarhus University Hospital
Aarhus, Denmark
|
| 127 |
NCT02518087 |
Recruiting |
Increased Adsorption Membranes During Cardiopulmonary Bypass |
- Cardiopulmonary Bypass
- Acute Kidney Injury
- Systemic Inflammatory Response Syndrome
|
|
Interventional |
Not Applicable |
- Hospital Universitari de Bellvitge
- Germans Trias i Pujol Hospital
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Baxter Healthcare Corporation
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Non presence of AKI-CS within the first 7 days after cardiac surgery.
- 90 day survival after cardiac surgery.
- ICU length of stay after cardiac surgery.
- (and 5 more...)
|
340 |
All |
18 Years and older (Adult, Senior) |
NCT02518087 |
SIRAKI 02-2015 |
|
May 2016 |
May 2019 |
May 2019 |
August 7, 2015 |
March 21, 2017 |
|
- Hospital German Trias i Pujol
Badalona, Barcelona, Spain - Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain - Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
|
| 128 |
NCT03254511 |
Recruiting |
Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer |
|
- Drug: Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable
- Radiation: Radiotherapy
- Drug: Chemotherapeutic Combinations
|
Interventional |
Phase 2 |
- Mashhad University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- clinical response
- pathologic response
- R staging (residual of tumor)
- heparin induced thrombocytopenia
|
100 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT03254511 |
941703
IRCT2016070628814N1 |
|
July 22, 2016 |
December 30, 2017 |
December 30, 2018 |
August 18, 2017 |
August 22, 2017 |
|
- Mashhad University of Medical Sciences
Mashhad, Khorasan Razavi, Iran, Islamic Republic of
|
| 129 |
NCT00700895 |
Recruiting |
Assessing the Clinical Benefits of a Pharmacogenetics-Guided Dosing Regiment for Calculating Warfarin Maintenance Dose |
- Indications for Warfarin Therapy
|
|
Interventional |
Phase 3 |
- National University Hospital, Singapore
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- No. of dosage titrations required to achieve targeted INR at 3 months of initializing warfarin.
- pharmacokinetics of warfarin R- and S-enantiomers
|
320 |
All |
18 Years and older (Adult, Senior) |
NCT00700895 |
PG01/11/06 |
|
August 2006 |
August 2016 |
August 2017 |
June 19, 2008 |
June 7, 2016 |
|
- University of Malaya Medical Centre
Kuala Lumpur, Malaysia - National University Hospital
Singapore, Singapore
|
| 130 |
NCT02948504 |
Not yet recruiting |
Chinese Small Intracranial Aneurysm Study (CSIAS) |
- Intracranial Aneurysm
- Unruptured Cerebral Aneurysm
- Treatment Side Effects
|
- Procedure: Coiling or Clipping
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Rupture of an unruptured aneurysm
- Regrowth of an unruptured aneurysm
- Recurrence and retreatment after coiling or clipping
- Poor outcome after coiling or clipping
|
500 |
All |
18 Years to 85 Years (Adult, Senior) |
NCT02948504 |
RJ2016144K1.0 |
|
December 2016 |
December 2018 |
December 2018 |
October 28, 2016 |
November 15, 2016 |
|
|
| 131 |
NCT01474564 |
Recruiting |
Feasibility of Obtaining and Characterizing Circulating Tumorigenic Cells in Patients With Pancreatic Adenocarcinoma |
- Pancreatic Adenocarcinoma
|
|
Observational |
|
- Memorial Sloan Kettering Cancer Center
- Adera Labs, LLC
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- isolating and enriching circulating tumorigenic cells
- successful gene expression profiling
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01474564 |
11-141 |
|
November 2011 |
November 2018 |
November 2018 |
November 18, 2011 |
October 4, 2017 |
|
- Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, United States - Memorial Sloan Kettering West Harrison
Harrison, New York, United States - Memorial Sloan Kettering Cancer Center
New York, New York, United States - (and 2 more...)
|
| 132 |
NCT03297203 |
Recruiting |
Innate Lymphoid Cells in Septic Shock |
|
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT03297203 |
2017-24 |
CriSIs |
August 2, 2017 |
August 2, 2018 |
December 31, 2018 |
September 29, 2017 |
October 2, 2017 |
|
- Hôpital de la Timone Assistance Publique Hôpitaux de Marseille
Marseille, France
|
| 133 |
NCT02825446 |
Recruiting |
Angioplasty of the Tibial Arteries Augmented Radio Frequency Denervation of the Popliteal Artery |
- Сhronic Ischemia of the Lower Extremities
- Atherosclerosis of the Tibial Arteries
- Lesion no More Than Two Tibial Arteries
- Steno-occlusive Lesion of the Tibial Arteries
|
- Procedure: angioplasty tibial arteries
- Procedure: angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the use"Vessix Renal Denervation System Balloon"
|
Interventional |
Not Applicable |
- Meshalkin Research Institute of Pathology of Circulation
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- the absence of thrombosis or stenosis of the popliteal artery
- Primary patency after intervention
- Secondary patency after intervention
- (and 3 more...)
|
40 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT02825446 |
N-RICP-873 |
ATRFPA |
May 2016 |
May 2018 |
May 2020 |
July 7, 2016 |
January 18, 2017 |
|
- NRICP
Novosibirsk, Russian Federation
|
| 134 |
NCT02464969 |
Recruiting |
Apixaban for the Acute Treatment of Venous Thromboembolism in Children |
|
- Drug: Apixaban
- Drug: Standard of Care
|
Interventional |
Phase 4 |
- Pfizer
- Bristol-Myers Squibb
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The composite of major and clinically relevant non major bleeding.
- A composite of all image confirmed and adjudicated symptomatic and asymptomatic recurrent VTE and VTE related mortality.
- Apixaban concentration
- Anti-Xa Levels
|
150 |
All |
up to 17 Years (Child) |
NCT02464969 |
B0661037
2014-002606-20
BMS STUDY NUMBER CV185-325 |
|
November 22, 2015 |
April 29, 2021 |
April 29, 2021 |
June 8, 2015 |
April 5, 2018 |
|
- Loma Linda University Children's Hospital
Loma Linda, California, United States - Loma Linda University Clinical Trial Center
Loma Linda, California, United States - Loma Linda University Investigational Drug Pharmacy
Loma Linda, California, United States - (and 93 more...)
|
| 135 |
NCT02596347 |
Recruiting |
The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD) |
- Chronic Beryllium Disease (CBD)
- Beryllium Sensitization (BeS)
|
- Procedure: Blood draw
- Procedure: bronchoscopy
|
Observational |
|
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- The primary outcome for the aims is the downregulation of Th1 cytokine TNFalpha with the inhibition of the JAK2 using siRNA and the inhibitor INCB018424, CEP-701 and TG101348 in CBD or overexpression of the JAK2 gene.
- The secondary outcomes for the aims are the changes in BeLPT and AMs phenotype from BeS, CBD and Healthy controls (HC).
|
12 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02596347 |
2877 |
|
April 2015 |
July 2017 |
|
November 4, 2015 |
September 22, 2016 |
|
- National Jewish Health
Denver, Colorado, United States
|
| 136 |
NCT02946944 |
Recruiting |
Sidlenafil in Combination With Oral Anticoagulants in Patients With Intermediate-high Risk of Pulmonary Embolism |
- Pulmonary Embolism
- Intermediate-high Risk
- Combination of Oral Anticoagulation Therapy and Sildenafil
|
- Drug: Sildenafil/apixaban
- Drug: apixaban
|
Interventional |
Phase 1 |
- Meshalkin Research Institute of Pathology of Circulation
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MSCT RV \ LV Index
- Echocardiogram RV \ LV Index
- Echocardiogram pressure in the pulmonary artery
- (and 5 more...)
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02946944 |
NRICP-45734 |
PSCAT |
October 2016 |
October 2020 |
October 2020 |
October 27, 2016 |
November 1, 2016 |
|
- Federal State Institution Academician E.N.Meshalkin Novosibirsk State Research Institute Of Circulation Pathology Rusmedtechnology
Novosibirsk, Russian Federation
|
| 137 |
NCT02618837 |
Recruiting |
Downstream Versus Upstream Strategy for the Administration of P2Y12 Receptor Blockers |
- Unstable Angina or Non ST Elevated Myocardial Infarction
|
- Procedure: Downstream strategy
- Procedure: Upstream strategy
|
Interventional |
Phase 4 |
- University of Padova
- Azienda Ospedaliera di Padova
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Incidence of NACE (Net Adverse Cardiac Events) at 30 days
- Incidence of NACE (Net Adverse Cardiac Events) at 12 months
- Incidence of single digit and composite of death from vascular causes, MI, stroke, TIA, severe recurrent ischemia, recurrent ischemia, or other arterial thrombotic event.
- (and 9 more...)
|
2520 |
All |
18 Years to 84 Years (Adult, Senior) |
NCT02618837 |
DUBIUS - 0015746 |
DUBIUS |
December 2015 |
March 2017 |
November 2018 |
December 1, 2015 |
January 20, 2016 |
|
- Azienda Ospedaliera di Padova
Padova, Veneto, Italy
|
| 138 |
NCT03310437 |
Not yet recruiting |
Cost Effectiveness if Primary PCI Versus Thrombolytic Therapy in Acute STEMI in Assiut University Hospital |
- ST Elevation Myocardial Infarction
|
|
Observational |
|
- Nahed Sameh Zaki
- Assiut University
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Compare between PPCI and thrombolytic therapy regarding over all cost in STEMI patients
|
200 |
All |
Child, Adult, Senior |
NCT03310437 |
81 |
|
November 1, 2017 |
October 1, 2018 |
August 1, 2019 |
October 16, 2017 |
October 16, 2017 |
|
- Assiut medicine faculty
Assiut, Egypt
|
| 139 |
NCT02498210 |
Recruiting |
IVM for Patients With Low Ovarian Response. Does it Improve IVFoutcomes and Does it Improve the Following IVF Cycle? |
|
- Other: In Vitro Maturation Procedure
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
25 |
Female |
25 Years to 45 Years (Adult) |
NCT02498210 |
SHEBA-14-1604-EM-CTIL |
|
October 2016 |
July 2019 |
July 2019 |
July 15, 2015 |
April 18, 2018 |
|
- Sheba Medical Center
Kiryat Ono, Israel
|
| 140 |
NCT01774058 |
Recruiting |
The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation |
- Diabetes
- Arteriosclerosis
- Peripheral Arterial Occlusive Disease
- Neuropathy
|
|
Interventional |
Phase 2 |
- Prim PD Dr Afshin Assadian
- Wilhelminenspital Vienna
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The measurement of the blood flow volume is done with the Sono TT FlowLab (em-Tec GmbH, Munich) ultrasound instrument on the common femoral artery in diabetics and non-diabetics after ilomedin administration.
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT01774058 |
ILOFLOW2.0 |
ILOFLOW |
October 2012 |
June 2018 |
June 2018 |
January 23, 2013 |
February 15, 2018 |
|
- Department of vascular and endovascular surgery, Georg Hagmüller Institute for Vascular Research Wilhelminenhospital
Vienna, Austria
|
| 141 |
NCT03148834 |
Not yet recruiting |
Dextran Use for Primary Angioplasty Protection in Acute Myocardial Infarction |
- Acute Myocardial Infarction With ST Elevation
|
- Procedure: Controlled Reperfusion
|
Interventional |
Not Applicable |
- Centro Cardiovascular Salta
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in ST segment elevation from baseline
- Total Mortality
- Infarct size
|
100 |
All |
18 Years and older (Adult, Senior) |
NCT03148834 |
052017 |
DUPAP |
June 1, 2017 |
July 1, 2018 |
July 1, 2019 |
May 11, 2017 |
May 11, 2017 |
|
|
| 142 |
NCT02853214 |
Recruiting |
Familial Dysglobulinemia |
|
- Genetic: Genetic analysis of peripheral blood samples
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Screening
|
- Data of a bank cells, clinically annotated, from families with at least 2 cases of dysglobulinemia and at least 1 case alive.plasma cell dysplasia
- Single Nucleotide Polymorphism array for identification of polymorphisms predictive of dysglobulinemia
|
3000 |
All |
18 Years and older (Adult, Senior) |
NCT02853214 |
2007-460 |
PreFamDys |
February 6, 2008 |
February 2019 |
February 2019 |
August 2, 2016 |
March 1, 2018 |
|
- CHU d'ABBEVILLE
Abbeville, France - CHU Groupe Hospitalier Sud Hématologie Clinique
Amiens, France - CH d'Avignon
Avignon, France - (and 42 more...)
|
| 143 |
NCT02856295 |
Not yet recruiting |
anti10a Levels in Women Treated With LMWH in the Postpartum Period |
|
|
Interventional |
Phase 4 |
- HaEmek Medical Center, Israel
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- clexane dosing method in order to achieve anti 10a level >0.2
- incidence of anti 10a level of >0.6
- incidence of vein thromboembolism
- incidence of bleeding events
|
116 |
Female |
18 Years and older (Adult, Senior) |
NCT02856295 |
EMC59-12 |
|
August 2016 |
February 2019 |
February 2019 |
August 4, 2016 |
August 4, 2016 |
|
|
| 144 |
NCT03297281 |
Recruiting |
Stop or Ongoing Oral Anticoagulation in Patients Undergoing Pvp (SOAP) |
- Benign Prostatic Hyperplasia
- Anticoagulant Adverse Reaction
|
- Other: Maintenance of OAC in surgery of BPH by PVP.
- Other: Discontinuation of OAC in surgery of BPH by PVP.
|
Interventional |
Not Applicable |
- Dr Vincent Misrai
- Boston Scientific Corporation
- Capionis
- Clinique Pasteur
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of patients with at least one complication classified higher or equal to grade 2 according to the Clavien classification related to maintenance of oral-anticoagulant (OAC) during the surgical resection of BPH by laser at 1 month
- Number of patients with at least one hemorrhagic complication related to maintenance of oral-anticoagulant (OAC) during the surgical resection of BPH by laser at 1 month, 3 months and 6 months
- Number of patients with at least one thrombotic complication related to maintenance of oral-anticoagulant (OAC) during the surgical resection of BPH by laser at 1 month, 3 months and 6 months
- (and 6 more...)
|
386 |
Male |
18 Years and older (Adult, Senior) |
NCT03297281 |
2017-A01236-47 |
SOAP |
October 30, 2017 |
November 30, 2019 |
May 1, 2020 |
September 29, 2017 |
January 24, 2018 |
|
- Clinique Pasteur
Toulouse, France
|
| 145 |
NCT03296033 |
Recruiting |
Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin |
- Anticoagulants and Bleeding Disorders
- Surgery
- Regional Anesthesia Morbidity
|
|
Interventional |
Phase 4 |
- Wake Forest University Health Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Anti-Xa activity levels following last treatment dose of enoxaparin
- Time point at which anti-Xa activity is lower than 0.2IU/mL using modeling
- Anti-Xa activity over time
- (and 3 more...)
|
150 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03296033 |
IRB00044503 |
|
October 24, 2017 |
June 2018 |
September 2018 |
September 28, 2017 |
November 6, 2017 |
|
- Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina, United States
|
| 146 |
NCT02935530 |
Recruiting |
Thromboprophylaxis After Surgery for Gynecologic Malignancy in China |
- Gynecologic Neoplasms
- Venous Thromboembolism
- Low Molecular Weight Heparin
- Argatroban
|
- Drug: s-LMWH
- Drug: LMWH
- Drug: Argatroban
|
Interventional |
Phase 3 |
- Huazhong University of Science and Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- VTE rate
- Bleeding rate
- Infection rate
|
300 |
Female |
16 Years to 70 Years (Child, Adult, Senior) |
NCT02935530 |
VTE-01 |
|
January 2016 |
June 2017 |
December 2017 |
October 17, 2016 |
October 17, 2016 |
|
- Tongji Hospital
Wuhan, Hubei, China
|
| 147 |
NCT03045406 |
Recruiting |
Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer |
|
- Drug: Apixaban
- Drug: Dalteparin
|
Interventional |
Phase 3 |
- Fadoi Foundation, Italy
- University of Perugia, Italy
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Recurrent venous thromboembolism
|
1168 |
All |
18 Years and older (Adult, Senior) |
NCT03045406 |
FADOI.03.2016 |
CARAVAGGIO |
April 13, 2017 |
December 2018 |
June 2019 |
February 7, 2017 |
April 18, 2018 |
|
- Brigham and Women's Hospital/DFCI
Boston, Massachusetts, United States - Cliniques universitaires Saint-Luc
Brussels, Belgium - Hôpital Europeen Georges Pompidou
Paris, France - (and 8 more...)
|
| 148 |
NCT03079596 |
Recruiting |
ERAS (Early Recovery After Surgery) Protocol After Laparoscopic Total Gastrectomy |
|
- Procedure: ERAS perioperative cares
- Procedure: Conventional perioperative cares
|
Interventional |
Not Applicable |
- Seoul National University Bundang Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tolerance of diet for 24 hours
- Analgesic-free
- Safe ambulation
- (and 4 more...)
|
100 |
All |
20 Years to 68 Years (Adult, Senior) |
NCT03079596 |
B-1608-357-006 |
|
April 1, 2017 |
April 2018 |
June 2018 |
March 14, 2017 |
September 5, 2017 |
|
- Seoul National University Bundang Hospital
Seongnam, Gyeonggi, Korea, Republic of
|
| 149 |
NCT01522417 |
Recruiting |
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention |
- Myocardial Infarction
- Acute Coronary Syndromes
- Unstable Angina
|
- Drug: Short Tirofiban
- Drug: Eptifibatide
- Drug: Long Tirofiban
|
Interventional |
Phase 2 |
- Medicure
- SCRI Development Innovations, LLC
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The composite incidence of death, PCI-related myocardial infarction, urgent target vessel revascularization or major bleeding
- The composite incidence of death, PCI-related myocardial infarction or urgent target vessel revascularization
|
550 |
All |
18 Years and older (Adult, Senior) |
NCT01522417 |
Medicure 11002 |
SAVI-PCI |
April 2012 |
March 2019 |
July 2019 |
January 31, 2012 |
March 12, 2018 |
|
- Osceola Regional Medical Center
Kissimmee, Florida, United States - Northside Hospital
Saint Petersburg, Florida, United States - Emory University Hospital Midtown
Atlanta, Georgia, United States - (and 10 more...)
|
| 150 |
NCT01895582 |
Recruiting |
Performance of IGRAs for TB Infection Diagnosis in Elderly |
|
|
Observational |
|
- Assistance Publique - Hôpitaux de Paris
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Number of positive, indeterminate, negative tests in each group
- Test results in clinical LTBI patients
- Correlation with TB-infection date
- (and 2 more...)
|
160 |
All |
75 Years and older (Senior) |
NCT01895582 |
P110131
2012-A00326-37 |
IGRage |
July 17, 2013 |
March 17, 2019 |
March 17, 2019 |
July 10, 2013 |
March 1, 2017 |
|
- Service de médecine interne
Bondy, France - Servive de Médecine Interne (Pr S. Herson)
Paris, France - Service de Médecine Interne, Diabete et Maladies Métaboliques
Strasbourg, France
|
Create an RSS feed from your search for:
Download the search results for: